|
gptkbp:instanceOf
|
gptkb:chemical_compound
gptkb:drug
|
|
gptkbp:approvalYear
|
2013
|
|
gptkbp:approvedBy
|
gptkb:India
|
|
gptkbp:ATCCode
|
none
|
|
gptkbp:brand
|
gptkb:Lipaglyn
|
|
gptkbp:CASNumber
|
848259-27-8
|
|
gptkbp:chemicalFormula
|
contains phenoxy group
contains thiazolidinedione moiety
|
|
gptkbp:clinicalTrialPhase
|
Phase 3 (India)
|
|
gptkbp:contraindication
|
severe renal impairment
hepatic impairment
|
|
gptkbp:developedBy
|
gptkb:Zydus_Cadila
|
|
gptkbp:hasMolecularFormula
|
C25H23ClO4
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
saroglitazar
|
|
gptkbp:indication
|
gptkb:type_2_diabetes_mellitus
dyslipidemia
hypertriglyceridemia
|
|
gptkbp:legalStatus
|
prescription only (India)
|
|
gptkbp:mechanismOfAction
|
PPAR alpha agonist
PPAR gamma agonist
|
|
gptkbp:molecularWeight
|
422.9 g/mol
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
edema
weight gain
increased liver enzymes
|
|
gptkbp:status
|
not approved by EMA
not approved by US FDA
|
|
gptkbp:usedFor
|
treatment of diabetic dyslipidemia
treatment of hypertriglyceridemia in type 2 diabetes mellitus
|
|
gptkbp:bfsParent
|
gptkb:Lipaglyn
|
|
gptkbp:bfsLayer
|
7
|